The Medicines and Healthcare products Regulatory Agency has set out how it intends to regulate through 2030, in a strategy built around speed, real world data and artificial intelligence. The document commits the agency to a higher value service that fast tracks scientific advice from 90 days to 45 days, halves the initial assessment target for qualifying Phase 1 trials to 14 days, and makes faster decisions on generics and biosimilars so the NHS captures savings earlier.
The AI commitments are structural. The MHRA will establish a Centre for AI and Digital Health, publish an AI Medicines Development Action Plan in 2027, build an AI enabled clinical trial protocol checker for sponsors, and develop an adaptive framework for AI as a medical device. The strategy follows the government’s October 6 acceptance of all 44 recommendations of the National Commission into the Regulation of AI in Healthcare, which proposed lifecycle monitoring of AI devices rather than a single premarket assessment.
On evidence, the agency plans wider use of hospital and genomics real world data, real time safety surveillance with the Health Data Research Service, simpler Yellow Card adverse event reporting, and a shift away from animal models toward human relevant methods such as organoids. It also promises a Women’s Health Plan this year, more diverse clinical studies, expanded reliance and recognition routes with trusted regulators including the US FDA, and continued recognition of CE marked devices.
Industry reaction was warm, with the ABPI saying the strategy is clear on speed, standards and measurement. The test is delivery: the commitments are guarantees the agency will now be judged against, and the Phase 1 timeline in particular puts the MHRA in direct competition with faster first in human jurisdictions for early stage trial placement.